

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>G01N 33/574, A61K 39/395, C07G 3/00, C07H 1/06, A61P 35/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/39589</b> <b>(43) International Publication Date:</b> 6 July 2000 (06.07.00)
<b>(21) International Application Number:</b> PCT/GB99/04382 <b>(22) International Filing Date:</b> 23 December 1999 (23.12.99) <b>(30) Priority Data:</b> 9828564.6 23 December 1998 (23.12.98) GB <b>(71) Applicant (for all designated States except US):</b> RADEMACHER GROUP LIMITED [GB/GB]; 6 St Andrew Street, London EC4A 3LX (GB). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> RADEMACHER, Thomas, William [US/GB]; Foxcombe, The Ridgeway, Boars Hill, Oxford OX1 5QU (GB). CARO, Hugo [AR/GB]; 44 Bedford Avenue, Barnet, Herts EN5 2EP (GB). <b>(74) Agents:</b> KIDDLE, Simon, J. et al.; Mewburn Ellis, York House, 23 Kingsway, London WC2B 6HP (GB).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> TREATMENT AND DIAGNOSIS OF CANCER USING INOSITOLPHOSPHOGLYCANS ANTAGONISTS		
<b>(57) Abstract</b>  Inositolphosphoglycans (IPGs), and in particular A-type substances comprising <i>myo</i> -inositol, are tumour autocrine factors (TAFs), that is factors which cause tumour cell proliferation. The use of A-type IPG antagonists for the treatment of cancer and a method for the diagnosis or prognosis of cancer based on the presence or amount of IPGs in a sample from a patient is disclosed.		